150 years dedicated to ophthalmology

The Chibret family A passion for trachoma

Paul CHIBRET, a military doctor based in Algeria developed an interest in trachoma: an eye disease that would fascinate him all his life.

The Chibret family S.F.O

Paul Chibret founds the French Society of Ophthalmology and develops innovative ophthalmic treatment along with his nephew Henry. 

The Chibret family Laboratoires Chibret

Henry Chibret sets up Chibret Laboratoires in Clermont-Ferrand, France.

On the picture : the second pharmacy of Henry Chibret in 1920
 

The Chibret family The leading ophthalmic company

Under Jean Chibret's management, Chibret Laboratoires becomes the leading ophthalmic company in Europe, Africa and the Middle East.

On the picture : the Chibret laboratories in the sixties
 

The Chibret family MSD-Chibret

MSD merges with Chibret to create Laboratoires MSD-Chibret. 

On the picture : packaging line at the boulevard Clémentel site in Clermont-Ferrand in the early sixities.

The start-up spirit Biophysic Medical

Jean's two sons, Jacques and Henri, take over in the late 70's. Jacques Chibret founds Biophysic Médical, specialized in laser and ultra-sound equipments for the treatment and diagnosis of eyes diseases. Biophysic Médical becomes a world leader.

The start-up spirit Transphyto

Henri Chibret creates Transphyto, an independent ophthalmic Research and Development laboratory, its innovations being entrusted to licensees for active marketing. 

The start-up spirit Laboratoires Théa

With the creation of the Théa Laboratories, Henri Chibret decides to directly commercialize the products developed by Transphyto's research.

Laboratoires Théa The first ABAK® bottle

The first ABAK^® bottle with the launch of an ocular anti-allergic.
 

The early days of the international expansion The first subsidiary

• Creation of the first subsidiary: Laboratorios Théa in Spain

The early days of the international expansion Théa Pharma Belgium

• Creation of Théa Pharma in Belgium

An eventful year Merger of Transphyto/Théa

• Merger of Transphyto and Laboratoires Théa
• Creation of Théa Pharma in Switzerland 
• Creation of Laboratoires Théa in Portugal

A year of acquisitions Laboratory Farmila

• Acquisition of an Italian Ophthalmic Laboratory, Farmila
• Acquisition of several Belpharma products

Extension of the product range Worldwide acquisition MSD products

Worldwide acquisition of a range of ophthalmic products from MSD laboratory.

A symbolic threshold A historic turnover

Consolidated revenues reach 100 million euros.

The expansion continues Europe and Africa

• Creation of an exclusive sales network in Africa and North Africa
• Creation of Théa Pharma in Germany

New implantation Théa Poland

The acquisitions continue Europhta

• Acquisition of Europhta Laboratories in Monaco

New location Joint-venture Spectrum Théa

• Creation of a joint-venture Spectrum Théa in Great Britain and Ireland

New range and location The international expansion continues

• Worldwide acquisition of a range of ophthalmic products from Novartis
• Launch of our activity in Russia

Product range Acquisition of a mydriatic insert

• Acquisition of the ophthalmic insert from Carl Zeiss Meditec

New products and affiliates Beyond the borders

• Acquisition of a wide range of ophthalmic products from Novartis in 30 European countries, as well as in Turkey, Canada and Mexico
• Creation of affiliates in Austria and Turkey
• Opening of the Nordic subsidiary in Sweden, covering Scandinavia and Finland

Expansion and Innovation Sharing knowledge

• Launch of the Théa Foundation
• Launch of the Tube with the Steri-Free^® technology for cosmetic products

New location Théa Russia

• Launch of the Théa Foundation
• Launch of the Tube with the Steri-Free^® technology for cosmetic products
• Creation of a new subsidiary in Russia

New location Théa Mexico

• Creation of Théa Mexico

New locations Théa in Morocco and Ukraine

• Creation of Théa in Morocco and Ukraine

New location Théa Dubaï

• Creation of a new subsidiary in Dubaï

New locations Théa Chili, Ireland, Romania and Canada

• Opening of new subsdiaries (Chili and Romania)
• Creation of joint-ventures (Ireland and Canada)

Entrepreneurship spirit Creation of Théa Open Innovation

• Creation of Théa Open innovation, a company 100% dedicated to innovation

New implantation Théa United States

Partnership Partnership with BioCorp

• Partnership between Théa Open Innovation and BioCorp to design, develop and manufacture connected medical devices to help patients suffering from blinding diseases such as glaucoma

New partnership Partnership with Coave Therapeutics

• Coave Therapeutics and Théa Open Innovation sign exclusive licensing, codevelopment and commercialization agreement for Europe for CTx-PDE6b, a novel gene therapy candidate in retinitis pigmentosa

New partnership Théa and Nevakar sign an exclusive licensing agreement

• Théa and Nevakar, a US-based company, entered into an exclusive licensing agreement

New partnership Partnership with Akorn

• Théa announces the acquisition of 7 Akorn-branded ophthalmic products